Literature DB >> 29482156

Berberine inhibits macrophage M1 polarization via AKT1/SOCS1/NF-κB signaling pathway to protect against DSS-induced colitis.

Yunxin Liu1, Xiang Liu2, Weiwei Hua2, Qingyan Wei2, Xianjun Fang3, Zheng Zhao1, Chun Ge1, Chao Liu1, Chen Chen1, Yifu Tao4, Yubing Zhu5.   

Abstract

Berberine has been reported to have protective effects in colitis treatment. However, the detailed mechanisms remain unclear. Herein, we demonstrated that berberine could protect against dextran sulfate sodium (DSS)-induced colitis in mice by regulating macrophage polarization. In the colitis mouse model, berberine ameliorated DSS-induced colon shortening and colon tissue injury. Moreover, berberine-treated mice showed significant reduction in the disease activity index (DAI), pro-inflammatory cytokines expression and macrophages infiltration compared with the DSS-treated mice. Notably, berberine significantly reduced the percentage of M1 macrophages. In vitro analysis also confirmed the inhibitory effects of berberine on macrophages M1 polarization in RAW267.4 cells. Further investigation showed that berberine promoted AKT1 expression in mRNA and protein level. Silence of AKT1 abolished the inhibitory effect of berberine on macrophages M1 polarization. The berberine-induced AKT1 expression promoted suppressers of cytokine signaling (SOCS1) activation, which inhibited nuclear factor-kappa B (NF-κB) phosphorylation. In addition, we also found that berberine activated AKT1/SOCS1 signaling pathway but inhibited p65 phosphorylation in macrophages in vivo. Therefore, we concluded that berberine played a regulatory role in macrophages M1 polarization in DSS-induced colitis via AKT1/SOCS1/NF-κB signaling pathway. This unexpected property of berberine may provide a potential explanation for its protective effects in colitis treatment.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AKT1; Berberine; Chronic inflammatory bowel disease; Macrophages polarization; SOCS1

Mesh:

Substances:

Year:  2018        PMID: 29482156     DOI: 10.1016/j.intimp.2018.01.049

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  22 in total

Review 1.  Altered nutrient status reprograms host inflammation and metabolic health via gut microbiota.

Authors:  Rachel M Golonka; Xia Xiao; Ahmed A Abokor; Bina Joe; Matam Vijay-Kumar
Journal:  J Nutr Biochem       Date:  2020-02-22       Impact factor: 6.048

Review 2.  Biologically active isoquinoline alkaloids covering 2014-2018.

Authors:  Xiao-Fei Shang; Cheng-Jie Yang; Susan L Morris-Natschke; Jun-Cai Li; Xiao-Dan Yin; Ying-Qian Liu; Xiao Guo; Jing-Wen Peng; Masuo Goto; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-29       Impact factor: 12.944

Review 3.  Berberine and its derivatives represent as the promising therapeutic agents for inflammatory disorders.

Authors:  Qiukai Lu; Yifan Fu; Heng Li
Journal:  Pharmacol Rep       Date:  2022-01-27       Impact factor: 3.024

4.  Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis.

Authors:  Lingfeng Sun; Xiangjiang Nie; Wenjie Lu; Qing Zhang; Wenyou Fang; Song Gao; Shengqi Chen; Rongfeng Hu
Journal:  AAPS PharmSciTech       Date:  2022-06-27       Impact factor: 4.026

Review 5.  Aging, Melatonin, and the Pro- and Anti-Inflammatory Networks.

Authors:  Rüdiger Hardeland
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

6.  Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88.

Authors:  Jing Gong; Jingbin Li; Hui Dong; Guang Chen; Xin Qin; Meilin Hu; Fen Yuan; Ke Fang; Dingkun Wang; Shujun Jiang; Yan Zhao; Wenya Huang; Zhaoyi Huang; Fuer Lu
Journal:  BMC Complement Altern Med       Date:  2019-11-19       Impact factor: 3.659

Review 7.  Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.

Authors:  Liang Wang; Yan Hu; Baohui Song; Yongjian Xiong; Jingyu Wang; Dapeng Chen
Journal:  Inflamm Res       Date:  2021-07-01       Impact factor: 4.575

8.  Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.

Authors:  Kai Niu; Qifang Li; Yuan Liu; Yi Qiao; Bingbing Li; Chao Wei; Kunrui Wang; Lu'an Cui; Canlei Zheng; Rong Wang; Li Zhang; Honghua Zhang; Bing Sun; Bin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-04       Impact factor: 2.629

9.  Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis.

Authors:  Heng Li; Chunlan Feng; Chen Fan; Yang Yang; Xiaoqian Yang; Huimin Lu; Qiukai Lu; Fenghua Zhu; Caigui Xiang; Zongwang Zhang; Peilan He; Jianping Zuo; Wei Tang
Journal:  Cell Death Dis       Date:  2020-04-24       Impact factor: 8.469

10.  Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions.

Authors:  Heng Li; Chen Fan; Huimin Lu; Chunlan Feng; Peilan He; Xiaoqian Yang; Caigui Xiang; Jianping Zuo; Wei Tang
Journal:  Acta Pharm Sin B       Date:  2019-09-05       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.